

FIG. I

Treatment:	-	UV	UV	UV	UV	TPA	TPA
Substrate:	WT	WT	WT	GST	Ala	WT	WT
Time:	0	5	30	30	30	5	30




FIG. 2A

Treatment:	-	TPA	TPA	TPA	TPA
Substrate:	WT	WT	WT	GST	Ala
Time:	0	10	30	30	30




FIG. 2B





FIG. 3A

In Vitro



In Vivo




FIG. 3B




FIG. 4A




FIG. 4B



FIG. 5A

FIG. 5B





FIG. 5C

Protein Gel

FIG.6A




³²P-Immobilized
Substrate

FIG.6B



³²P-Exogenous
Substrate

FIG.6C






FIG. 7A




FIG. 7B



FIG. 7C




FIG.9A




FIG.9B




FIG.11A

FIG.11B

FIG.12A





FIG.12B









FIG.12C




FIG.13A




FIG.13B

FIG.13C




FIG.14

FIG.15A

Erk-1 Mut →




FIG.15C

Erk-1 Mut →






FIG.15B

MBP →



FIG.15D

MBP →



CsA
+
- T A T/A T/A
MW.

- 106
- 80
- 49.5
- 32.5

FIG.16A

CsA	+	-	-	-	-
anti-CD28	+	+	-	+	-
anti-CD3	+	+	+	-	-

JNK(55) →
JNK(46) →



FIG.16B

CsA	-	-	-	-	+
anti-CD28	-	-	+	+	+
anti-CD3	-	+	-	+	+

GSTcJun →



MBP →




FIG.16C

	1	2	3	4	5	6	7	8	9	10	11
CsA	-	-	-	-	-	-	+	-	+	-	+
anti-CD28	-	-	-	-	+	-	-	-	-	+	+
anti-CD3	-	-	-	+	-	-	-	+	+	-	-
A	-	-	+	-	-	+	+	-	-	-	-
T	-	+	-	-	-	+	+	+	+	+	+

GST-cJun →



MBP →

